Dr. Reddy's Laboratories Ltd. 500124 shares slid 1.27% to 1,354.20 Indian rupees Friday, on what proved to be an all-around ...

Geode Capital Management LLC increased its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 109.3% ...

DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...

Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Benchmark NSE Nifty50 index was down 141.81 points at 23566.1, while the BSE Sensex was 484.38 points at 77714.73. Among the ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Stocks like Tata Steel, Dr Reddy’s Laboratories, WPIL, Rail Vikas Nigam, Mahindra and Mahindra, Mankind Pharma, CESC, ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.